{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:40:18Z","timestamp":1785289218091,"version":"3.55.0"},"reference-count":76,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Lipoprotein (a) is a complex lipid molecule that has sparked immense interest in recent years, after studies demonstrated its significant association with several cardiovascular conditions. Lp(a) promotes cardiovascular disease through its combined proatherogenic, pro-inflammatory, and prothrombotic effects. While the measurement of Lp(a) has become widely available, effective methods to reduce its concentration are currently limited. However, emerging data from ongoing clinical trials involving antisense oligonucleotides have indicated promising outcomes in effectively reducing Lp(a) concentrations. This may serve as a potential therapeutic target in the management and prevention of myocardial infarction, calcific aortic stenosis, and cerebrovascular accidents. In contrast, the role of Lp(a) in atrial fibrillation, in-stent restenosis, cardiac allograft vasculopathy, and bioprosthetic aortic valve degeneration remains unclear. This review article aims to thoroughly review the existing literature and provide an updated overview of the evidence surrounding the association of Lp(a) and these cardiovascular diseases. We seek to highlight controversies in the existing literature and offer directions for future investigations to better understand Lp(a)\u2019s precise role in these conditions, while providing a summary of its unique molecular characteristics.<\/jats:p>","DOI":"10.3390\/ijms252011029","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T06:46:33Z","timestamp":1728888393000},"page":"11029","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lipoprotein (a) as a Cardiovascular Risk Factor in Controversial Clinical Scenarios: A Narrative Review"],"prefix":"10.3390","volume":"25","author":[{"given":"Hesham M.","family":"Abdalla","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9729-9961","authenticated-orcid":false,"given":"Ahmed K.","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed E.","family":"Khedr","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-8485","authenticated-orcid":false,"given":"Juan M.","family":"Farina","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6459-9767","authenticated-orcid":false,"given":"Isabel G.","family":"Scalia","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7212-435X","authenticated-orcid":false,"given":"Mohammed Tiseer","family":"Abbas","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal A.","family":"Awad","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3979-0609","authenticated-orcid":false,"given":"Nima","family":"Baba Ali","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadera N.","family":"Bismee","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sogol","family":"Attaripour Esfahani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Javadi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4695-8436","authenticated-orcid":false,"given":"Milagros","family":"Pereyra","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7880","authenticated-orcid":false,"given":"Said","family":"Alsidawi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7081-4286","authenticated-orcid":false,"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","article-title":"Executive Summary: Heart Disease and Stroke Statistics\u20142016 Update: A Report From the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1194\/jlr.R071571","article-title":"Lipoprotein (a): A historical appraisal","volume":"58","author":"Kostner","year":"2017","journal-title":"J. Lipid Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2009.12.036","article-title":"Lipoprotein(a) and ischemic heart disease\u2014A causal association? A review","volume":"211","author":"Kamstrup","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_5","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: A report of the american college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) Is Markedly More Atherogenic Than LDL","volume":"83","author":"Adiels","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jacl.2018.07.014","article-title":"In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members","volume":"12","author":"Zawacki","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrcardio.2018.3","article-title":"Advances in lipid-lowering therapy through gene-silencing technologies","volume":"15","author":"Nordestgaard","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2019.10.044","article-title":"Interaction of lipoprotein(a) with low-density lipoprotein cholesterol on first incident acute myocardial infarction","volume":"501","author":"Hu","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_10","first-page":"125","article-title":"Lipoprotein(a): Is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?","volume":"31","author":"Langsted","year":"2020","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1161\/STROKEAHA.106.480657","article-title":"Lipoprotein (a) and Stroke","volume":"38","author":"Smolders","year":"2007","journal-title":"Stroke"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Wang, Z., Ji, R., Wang, Y., Zhang, Y., and Yu, K. (2024). Relationship between carotid atherosclerosis and lipoprotein (a) in patients with acute ischemic stroke. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1383771"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14779072.2023.2197593","article-title":"Lipoprotein(a): Cardiovascular risk and emerging therapies","volume":"21","author":"Fujino","year":"2023","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J. Clin. Lipidol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","article-title":"2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12944-022-01728-5","article-title":"Low lipoprotein(a) concentration is associated with atrial fibrillation: A large retrospective cohort study","volume":"21","author":"Tao","year":"2022","journal-title":"Lipids Health Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e008401","DOI":"10.1161\/CIRCEP.120.008401","article-title":"Lp(a) (Lipoprotein [a]) and Risk for Incident Atrial Fibrillation","volume":"13","author":"Garg","year":"2020","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-021-01482-0","article-title":"Association of Lipoprotein (a) variants with risk of cardiovascular disease: A Mendelian randomization study","volume":"20","author":"Xia","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.jacc.2022.02.018","article-title":"Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study","volume":"79","author":"Chong","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102024","DOI":"10.1016\/j.cpcardiol.2023.102024","article-title":"Association Between Lipoprotein (a) and Risk of Atrial Fibrillation: A Systematic Review and Meta-analysis of Mendelian Randomization Studies","volume":"49","author":"Singh","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.numecd.2021.02.011","article-title":"Causal effects of plasma lipids on the risk of atrial fibrillation: A multivariable mendelian randomization study","volume":"31","author":"Jiang","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e007372","DOI":"10.1161\/JAHA.117.007372","article-title":"Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Athero-sclerosis Risk in Communities) Study","volume":"6","author":"Aronis","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1161\/CIRCEP.113.001378","article-title":"Paradoxical Association of Lipoprotein Measures With Incident Atrial Fibrillation","volume":"7","author":"Mora","year":"2014","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0735-1097(98)00684-6","article-title":"Lipoprotein(a) and coronary thrombosis and restenosis after stent placement","volume":"33","author":"Wehinger","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/01.CIR.98.12.1172","article-title":"Plasma Lipoprotein(a) Is Not a Predictor for Restenosis After Elective High-Pressure Coronary Stenting","volume":"98","author":"Ribichini","year":"1998","journal-title":"Circulation"},{"key":"ref_28","first-page":"158","article-title":"Does Lipoprotein (a) Level Have a Predictive Value in Restenosis after Coronary Stenting?","volume":"2","author":"Khosravi","year":"2011","journal-title":"Int. J. Prev. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.atherosclerosis.2013.01.014","article-title":"Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: Meta-analysis of 9 cohort studies","volume":"227","author":"Qin","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1253\/circj.69.644","article-title":"Association Between Plasma Lipoprotein(a) Concentration and Restenosis After Stent Implantation","volume":"69","author":"Kamitani","year":"2005","journal-title":"Circ. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10554-022-02736-3","article-title":"Lipoprotein (a) is related to In-Stent neo-atherosclerosis incidence rate and plaque vulnerability: Optical Coherence Tomography Study","volume":"39","author":"Yuan","year":"2022","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Mahmoud, A.K., Farina, J.M., Awad, K., Ali, N.B., Pereyra, M., Scalia, I.G., Abbas, M.T., Allam, M.N., A Kamel, M., and A Abu Rmilah, A. Lipoprotein(a) and long-term in-stent restenosis after percutaneous coronary intervention. Eur. J. Prev. Cardiol., 2024.","DOI":"10.1093\/eurjpc\/zwae212"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e13794","DOI":"10.1111\/ctr.13794","article-title":"Cardiac allograft vasculopathy: Insights on pathogenesis and therapy","volume":"34","author":"Lee","year":"2020","journal-title":"Clin. Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/0140-6736(92)92756-6","article-title":"Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients","volume":"340","author":"Barbir","year":"1992","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/hj.1998.v136.89581","article-title":"Lipoprotein(a) levels and heart transplantation atherosclerosis","volume":"136","author":"Chang","year":"1998","journal-title":"Am. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/heartjnl-2023-322987","article-title":"Role of lipoprotein(a) concentrations in bioprosthetic aortic valve degeneration","volume":"110","author":"Farina","year":"2023","journal-title":"Heart"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/ehjci\/jeac274","article-title":"Serum lipoprotein(a) and bioprosthetic aortic valve degeneration","volume":"24","author":"Botezatu","year":"2023","journal-title":"Eur. Heart J.-Cardiovasc. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"(2024, August 31). Lipoprotein(a)\u2014Structure, Epidemiology, Function and Diagnostics of a Cardiovascular Risk Marker. Available online: https:\/\/benthamopenarchives.com\/abstract.php?ArticleCode=TOCCHEMJ-1-79.","DOI":"10.2174\/1874241600801010079"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jprot.2014.04.030","article-title":"Absolute quantification of apolipoproteins and associated proteins on human plasma lipoproteins","volume":"106","author":"Williams","year":"2014","journal-title":"J. Proteom."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0022-2275(20)34933-6","article-title":"Learning about the structure and biology of human lipoprotein [a] through dissection by enzymes of the elastase family: Facts and speculations","volume":"38","author":"Scanu","year":"1997","journal-title":"J. Lipid Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1155\/2013\/563717","article-title":"Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment","volume":"35","author":"Cai","year":"2013","journal-title":"Dis. Markers"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.mayocp.2013.09.003","article-title":"Lipoprotein(a), Cardiovascular Disease, and Contemporary Management","volume":"88","author":"Jacobson","year":"2013","journal-title":"Mayo Clin. Proc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Deo, R.C., Wilson, J.G., Xing, C., Lawson, K., Kao, W.H.L., Reich, D., Tandon, A., Akylbekova, E., Patterson, N., and Mosley, T.H. (2011). Single-Nucleotide Polymorphisms in LPA Explain Most of the Ancestry-Specific Variation in Lp(a) Levels in African Americans. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0014581"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e10044942014","DOI":"10.1371\/journal.pgen.1004494","article-title":"Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population","volume":"10","author":"Lim","year":"2014","journal-title":"PLOS Genet."},{"key":"ref_49","first-page":"167","article-title":"Structure-function relationships in apolipoprotein(a): Insights into lipoprotein(a) assembly and pathogenicity","volume":"15","author":"Koschinsky","year":"2004","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/002215549704500408","article-title":"Immunolocalization of Lipoprotein(a) in Wounded Tissues","volume":"45","author":"Yano","year":"1997","journal-title":"J. Histochem. Cytochem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/qjmed\/93.2.75","article-title":"Lipoprotein(a): From ancestral benefit to modern pathogen?","volume":"93","author":"Lippi","year":"2000","journal-title":"QJM Int. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Cui, K., Wang, H.-Y., Yin, D., Zhu, C., Song, W., Wang, H., Jia, L., Zhang, D., Song, C., and Feng, L. (2021). Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.807925"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e033562","DOI":"10.1161\/JAHA.123.033562","article-title":"Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi-Ethnic Study of Atherosclerosis","volume":"13","author":"Bhatia","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nature00804","article-title":"Subendothelial retention of atherogenic lipoproteins in early atherosclerosis","volume":"417","author":"Gustafsson","year":"2002","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1161\/CIRCULATIONAHA.119.042863","article-title":"Pathogenic Autoimmunity in Atherosclerosis Evolves From Initially Protective Apolipoprotein B 100 \u2013Reactive CD4 + T-Regulatory Cells","volume":"142","author":"Wolf","year":"2020","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical Trial Design for Lipoprotein(a)-Lowering Therapies","volume":"81","author":"Malick","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) Reduction in Persons with Cardiovascular Disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: State of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease","volume":"387","author":"Rosenson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial Fibrillation","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0008-6363(02)00222-5","article-title":"Molecular mechanisms of remodeling in human atrial fibrillation","volume":"54","author":"Brundel","year":"2002","journal-title":"Cardiovasc. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","article-title":"Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve","volume":"132","author":"Bouchareb","year":"2015","journal-title":"Circulation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2020.08.026","article-title":"Lipid levels, atrial fibrillation and the impact of age: Results from the LIPIDOGRAM2015 study","volume":"312","author":"Harrison","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Ding, M., Wennberg, A., Gigante, B., Walldius, G., Hammar, N., and Modig, K. (2022). Lipid levels in midlife and risk of atrial fibrillation over 3 decades\u2014Experience from the Swedish AMORIS cohort: A cohort study. PLOS Med., 19.","DOI":"10.1371\/journal.pmed.1004044"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): Impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jacc.2022.05.017","article-title":"Coronary In-Stent Restenosis","volume":"80","author":"Giustino","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4244\/EIJ-D-20-00539","article-title":"Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis","volume":"17","author":"Nakamura","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.2169\/internalmedicine.1609-23","article-title":"Efficacy of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitor Treatment for Repeated In-stent Restenosis in a Coronary Artery","volume":"62","author":"Akiyama","year":"2023","journal-title":"Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/eurheartj\/ehy334","article-title":"Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting","volume":"39","author":"Verbeek","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.transproceed.2023.09.009","article-title":"Elevated Lipoprotein A Levels and Development of Moderate or Severe Cardiac Allograft Vasculopathy in Patients with Heart Transplants","volume":"55","year":"2023","journal-title":"Transplant. Proc."},{"key":"ref_72","first-page":"1","article-title":"Calcific aortic stenosis","volume":"2","author":"Lindman","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1161\/CIRCULATIONAHA.104.486738","article-title":"Spectrum of Calcific Aortic Valve Disease","volume":"111","author":"Freeman","year":"2005","journal-title":"Circulation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e018506","DOI":"10.1161\/JAHA.120.018506","article-title":"Degeneration of Bioprosthetic Heart Valves: Update 2020","volume":"9","author":"Kostyunin","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/HCO.0000000000000372","article-title":"Incidence, risk factors, clinical impact, and management of bioprosthesis structural valve degeneration","volume":"32","author":"Pibarot","year":"2017","journal-title":"Curr. Opin. Cardiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/20\/11029\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:12:57Z","timestamp":1760112777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/20\/11029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":76,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["ijms252011029"],"URL":"https:\/\/doi.org\/10.3390\/ijms252011029","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}